Leading Medical Experts to Gather at Nanotechnology for Cancer Symposium During Nanotech 2007 in Santa Clara, California in May 2007
Officials from National Cancer Institute, National Institute of Health, FDA, Genentech, Stanford University, UCLA and Northeastern University among leaders attending to discuss nanotechnology’s promise for preventing, diagnosing, and treating cancer
SANTA CLARA, Calif.--(BUSINESS WIRE)--Many of the world’s top experts on nanotechnology’s use for fighting cancer – in prevention, detection and treatment -- will speak at the CancerNano 2007, May 20-24, 2007 in Santa Clara, Calif. Slated speakers for CancerNano 2007 include high-ranking officials from National Cancer Institute, the National Institutes of Health, the U.S. Food and Drug Administration and leading researchers from Genentech, Pfizer, Stanford University, UCLA, and the California Institute of Technology.
“Over the last few years, we have seen tremendous growth and progress by combining researchers of all disciplines in a focused fight to eradicate cancer. We’re proud to continue this effort with CancerNano 2007.”
The ‘CancerNano 2007 Symposium” is co-sponsored by NCI and NIH, and produced in conjunction with Nano Science and Technology Institute’s (NSTI) Nanotech 2007, the leading nanotechnology conference in the U.S., where some 4,000 nanotechnology experts from science, research, commercial and government interests are expected to gather.
“At CancerNano 2007, many of the most respected leaders from research and regulatory communities will help us illustrate to the nano and cancer research communities the valuable role nanotechnology is about to play in the fight against cancer, across a broad range of areas,” CancerNano 2007 co-chair Mansoor Amiji said. Dr. Amiji is also a noted cancer researcher focusing on using nano techniques for drug and gene therapy at the Department of Pharmaceutical Sciences at Northeastern University in Boston, Mass.
“With so much basic nanotechnology research work holding so much promise, we also hope CancerNano2007 will show researchers how they could more easily move their nanoscience research from the lab into clinical trials, and at the same time have regulators help us more quickly deliver to patients safe and effective cancer treatments,” Dr. Amiji added.
“As part of our ongoing mission to encourage the growth and adoption of Nanotechnology sciences, we are privileged to be working with NCI, FDA, NIH and leading cancer scientists from around the world to expand the bridges between these two communities.” said Matthew Laudon, Executive Director for NSTI. “Over the last few years, we have seen tremendous growth and progress by combining researchers of all disciplines in a focused fight to eradicate cancer. We’re proud to continue this effort with CancerNano 2007.”
CancerNano Speaker Highlights
CancerNano 2007 will feature two well-known keynoters, representing the government and private sector nanotechnology research for cancer.
• NCI Deputy Director, Anna D. Barker, one of NCI’s top experts on the state of research for using nanotechnology to fight cancer; and
• Nicholas van Bruggan, who as Associate Director for Biomedical Imaging at Genentech is one of the biotechnology giant’s most knowledgeable executives on using nanotechnology for drug discovery.
CancerNano 2007 will also host more than 20 sessions and will address many of the most cutting-edge questions facing researchers looking to move basic research findings from the lab and into clinical trials. Among the CancerNano 2007 topics are:
• Designing and testing more complex nanosystems that would ‘self-assemble’ in the body to provide on-going data for monitoring cancer treatments;
• How computer modeling and nanochemistry can help design and build new synthetic materials
• The best ways to ensure the use of safe nanoparticles for cancer diagnostics and imaging.
• Building nano-carriers for drug delivery and gene therapy
• Exploring nano-doses of electromagnetics and heat to attack tumors from the inside, and
• How nano-assembled drugs and therapies (based on already-approved procedures and compounds) could enable nano-scale medicines to be regulated under rules for ‘generics’ medicines.
For more information on speakers and sessions at CancerNano 2007: A Symposium on Nanotechnology for Cancer Prevention, Diagnosis and Treatment” go to: http://www.nsti.org/Nanotech2007/symposia/Cancer_Diagnostics_Imaging_ Treatment.html (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
For information on Nanotech 2007 and BioNano 2007 for to: http://www.nsti.org/Nanotech2007
About CancerNano 2007
CancerNano 2007 is the 3rd annual nanotechnology cancer symposium, co-sponsored by National Cancer Institute, National Institute of Health and produced by Nano Science and Technology Institute (NSTI). CancerNano 2007 is also part of NCI’s on-going efforts to harness the power of nanotechnology to radically change the way we diagnose, image and treat cancer. CancerNano 2007 will run in parallel with the Nanotech 2007 and the BioNano 2007 providing a unique multidisciplinary environment directed towards addressing the challenges of cancer research and treatment. CancerNoano 2007 is co-chaired by Northeastern University’s Dr. Mansoor Amiji and Dr. Vladimir Torchilin both in the Department of Pharmaceutical Sciences.
About Nano Science and Technology Institute (NSTI)
The Nano Science and Technology Institute (NSTI; www.nsti.org) is chartered with the advancement and integration of nano and other advanced technologies through education, collaboration and research services. NSTI accomplishes this mission through its offerings of continuing education programs, conventions, scientific and business publishing and custom research services. NSTI produces the annual Nanotech 200x conference and trade show (now in its 10th year), the world’s largest event to focus on nanoscience and nanotechnology, attracting more than 4,000 industrial, academic, business and governmental attendees from around the world.